ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PYPD
APYX (21) SKYA (43) LUNG (38) NYXH (45) ⌘ Pro Terminal →

PolyPid Ltd. (PYPD) — RQD Stock Rating Cockpit

$5.42 +0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.42

PolyPid Ltd. (PYPD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $109.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PYPD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PolyPid Ltd. (NASDAQ: PYPD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $5.42 (+0.56% 1D, market cap $109.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PYPD ranks #444 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PYPD compare to APYX and SKYA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), PYPD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APYX (Apyx Medical Corporation) holds a E grade (21/100 RQD, P/E N/A, ROIC -28.9%, cap $109.5M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, PYPD leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PYPD?
▼

Per PYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611842), PolyPid Ltd. generated $92.3M in revenue (+17.6% YoY), -$34.2M in net income, and -$28.1M in free cash flow against $22.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.42 (-0.09%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D+
Cash (6)Whales (11)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
$6 Bull$5 Base$4 Bear
📬 FREE PYPD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PYPD)Realized 20D OHLCV Swing Band: ±10.8%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY PYPD SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±10.8% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)

FRED Regime × Technicals: 82% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$4.88+5.5% Next Q
Q2 (-2Q)
36
Grade E$5.15+12% Next Q
Q3 (-1Q)
38
Grade E$5.77-6.1% Next Q
Current
41
Grade D-$5.42-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PYPD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PYPD currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.21) and Max Pain ($5.69) forces dealer call-delta covering toward $6.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PYPD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PYPD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
53.430 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE82% OF RANGE
L: $4$5.42H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on PYPD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and -24.74% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

14/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like PYPD
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PYPD)

  • ✓Walkthrough of PYPD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PYPD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.98%▲ ASCENDING CHANNEL
2026-11-03O $5.59H $5.59L $5.39C $5.42VOL 101.6K
RES: $5.86SUP: $4.82SMA50: $5.21SMA200: $4.74
$5.99$5.36$4.72$4.09$3.45RES $5.86SUP $4.82$5.422026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PYPD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PYPD Butterfly Map → + Track PYPD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PYPD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PYPD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PYPD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PYPD)

Health Care Rank #444 of 1015 ⚔️ APYX vs PYPD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PYPD vs. APYX, SKYA, LUNG, NYXH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PolyPid Ltd. (PYPD) ranks #444 by composite RQD confidence (41/100, grade D-) and #639 by equity capitalization ($109.5M). Within this direct 5-issuer industry benchmark cohort, PYPD leads on earnings valuation at N/A trailing P/E, while APYX leads on capital efficiency and profitability with -28.9% ROIC and 62.5% gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with PYPD at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PYPD ACTIVE
PolyPid Ltd.
D- 41/100 — — -35.0% +0.56% $109.5M Benchmark Subject
APYX
Apyx Medical Corporation
E 21/100 — 62.5% -28.9% 0.00% $109.5M /apyx-vs-pypd →
SKYA
SkyAI Inc.
D- 43/100 — -30.0% -35.0% -1.35% $128.4M /skya-vs-pypd →
LUNG
Pulmonx Corporation
D- 38/100 — 74.2% -35.0% -14.14% $129.1M /lung-vs-pypd →
NYXH
Nyxoah SA
D 45/100 — — — +0.99% $87.2M /nyxh-vs-pypd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611842 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PolyPid Ltd. (PYPD) reported GAAP revenue of $92.3M (+17.6% vs. FY2024 revenue of $78.5M , and +44.2% cumulative change since FY2023) , GAAP net income of -$34.2M, operating cash flow of -$27.9M, and free cash flow of -$28.1M (-27.5% YoY). On the balance sheet, PYPD closed FY2025 with $22.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $92.3M -$34.2M -$27.9M -$28.1M $22.3M —
FY2024 (FY) 2024-12-31 $78.5M -$29.0M -$22.0M -$22.0M $25.2M $634.0K
FY2023 (FY) 2023-12-31 $64.0M -$23.9M -$17.2M -$17.2M — —

3. PYPD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PolyPid Ltd. (NASDAQ: PYPD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $5.42 (+0.56% 1D, market cap $109.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PYPD ranks #444 in composite RQD confidence.

How does PYPD compare to APYX and SKYA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PYPD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APYX (Apyx Medical Corporation) holds a E grade (21/100 RQD, P/E N/A, ROIC -28.9%, cap $109.5M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, PYPD leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PYPD?

Per PYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611842), PolyPid Ltd. generated $92.3M in revenue (+17.6% YoY), -$34.2M in net income, and -$28.1M in free cash flow against $22.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PYPD trading relative to its 50-day, 200-day, and 52-week technical levels?

PYPD last traded at $5.42 (+0.56% on volume of 205,811 shares), positioning the stock +4.03% above its 50-day simple moving average ($5.21) and +14.35% above its 200-day simple moving average ($4.74). Across its 52-week range of $3.50 to $5.84, PYPD sits at the 82.1% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($4.83 to $6.01).

Direct Sub-Reports: PYPD RQD Cockpit PYPD 12M Forecast PYPD Earnings & Move PYPD Dividends & DRIP PYPD Insiders & 13F PYPD Whale Options PYPD Profit Sankey PYPD News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PYPD — PolyPid Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PolyPid Ltd. (PYPD) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $5.42 (+0.56% 1D, market capitalization $109.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -24.74%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

And profile, PolyPid Ltd. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. The profile lists a market capitalization of $0.1B. Per the recent news wire, the company's pipeline includes a drug candidate designed to keep antibiotics in wounds for weeks and a candidate for diabetic foot infections. —: the customer base and detailed revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PolyPid Ltd. (PYPD) reported $92.3M in annual revenue (up from $78.5M in FY2024, +17.6% YoY) and -$34.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($64.0M revenue, -$23.9M net income) through FY2025, PYPD scaled operating cash flow to -$27.9M and free cash flow to -$28.1M, backed by $22.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -24.74% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $3.50 – $5.84 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order bottlenecks can be mapped from the source data. —: supplier and customer relationships, manufacturing partners, and sector peer correlations. The beta of 1.0 per the market data indicates market-level sensitivity, but sector-specific ripple effects cannot be quantified from the sources provided.

  • Key Question #1: Can PYPD sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $92.3M and free cash flow of -$28.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PYPD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PYPD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PolyPid Ltd. (PYPD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PYPD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PYPD Bull vs. Bear Conversation Board — What's Your Call at $5.42?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PYPD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PYPD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $6.58 (+22.1%)
📌 Pinned Debate

An Oppenheimer Outperform rating and a pipeline expansion with a 2,185-patient infection analysis signal analyst and clinical momentum.

Picked up a starter position in PYPD in my $100K Virtual Cash book at $5.39. An Oppenheimer Outperform rating and a pipeline expansion with a 2,185-patient infection analysis signal analyst and clinical momentum.. Trading inside a $3.50–$5.84 52-week range with -24.74% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $4.58 (-15.0%)
Spot @ $5.39

Zero reported revenue, a -35% ROIC, and cash falling from $15.6M to $6.4M point to a cash burn that outpaces the balance sheet.

Zero reported revenue, a -35% ROIC, and cash falling from $15.6M to $6.4M point to a cash burn that outpaces the balance sheet.. Look at the math on PYPD: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $4.74 before getting long.

LIVE TAPE